章旭耀
生物药物学, 青年研究员, 博士生导师

姓      名

 章旭耀

性      别

 男

职      称

 青年研究员

学      历

 博士

电      话

 021-51980129

传      真

 021-51980035

电子邮件

 xuyaozhang@fudan.edu.cn

个人主页

通讯地址

 上海市张衡路826号复旦大学药学院

 

教育经历
2015.9 – 2018.7  复旦大学药学院  博士

2012.9 – 2015.7  郑州大学药学院  硕士

2008.9 – 2012.7  郑州大学药学院  本科


工作经历
2020.9 – 至今   复旦大学生物药物学系  青年研究员

2018.7 – 2020.8  宾夕法尼亚大学肿瘤生物学  博士后


承担科研项目情况

1. 国家自然科学基金委，青年科学基金项目，2023-2025，主持

2. 上海市科学技术委员会，科技创新行动计划，2021-2024，主持

3. 复旦大学，复旦大学引进人才科研基金，2021-2025，主持

4. 国家自然科学基金委，面上项目，2018-2021，参与


获奖及荣誉

2021  上海市青年科技英才“扬帆计划”入选者

2020  上海“海外高层次人才引进计划”入选者

2018  上海市普通高等学校优秀博士毕业生

2017  ESMO Immuno Oncology Congress 2017. Poster Discussion & Travel Award

2017  宝钢教育奖学金特等奖

2017  JSMO Annual Meeting. Oral Presentation & Travel Award

2016  ESMO Asia 2016 Congress. Poster Presentation & Travel Award

2016  JSMO Annual Meeting. Oral Presentation & Travel Award

2015  河南省普通高等学校优秀毕业生

2014  研究生国家奖学金


研究方向

1. 新型免疫治疗药物研发

2. 微环境与肿瘤免疫治疗机制研究


代表性论著

  1. Xu C, Ju D*, Zhang X*. Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy. Frontiers in Immunology. 2022;13:923598.

  2. Wang R, Liu H, He P, An D, Guo X, Zhang X*, Feng M*. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells. Frontiers in Immunology. 2022;13:947756.

  3. Xu C, Ju D*, Zhang X*.Chimeric antigen receptor T cell therapy: challenges and opportunities in lung cancer. Antibody Therapeutics. 2022;5:73-83.

  4. Feng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona BW, Gade TP, Schrader J, Metz DC, June CH, Hua X*. Eradication of Neuroendocrine Tumors by CDH17CAR T Cells Without Toxicity to Normal Tissue. Nature Cancer. 2022;3:581-594.

  5. Zhang X, Wang Y, Fan J, Chen W, Luan J, Mei X, Wang S, Li Y, Ye L,Li S, Tian W, Yin K*, Ju D*. Blocking CD47 efficiently potentiated therapeuticeffects of anti-angiogenic therapy in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 2019; 7:346.

  6. Zhang X, Fan J, Ju D*. Insights into CD47/SIRPα axis-targetingtumor immunotherapy. Antibody Therapeutics. 2018; 1:37-42.

  7. Zhang X, Chen W, Fan J, Wang S, Xian Z, Luan J, Li Y, Wang Y, NanY, Luo M, Li S, Tian W, Ju D*. Disrupting CD47-SIRPα axis alone or combinedwith autophagy depletion for the therapy of glioblastoma. Carcinogenesis. 2018;39:689-699.

  8. Zhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, Wang Y, Liang Y, LiS, Tian W, Ju D*. Inhibition of autophagy potentiated the anti-tumor effects ofVEGF and CD47 bispecific therapy in glioblastoma. Applied Microbiology and Biotechnology. 2018; 102:6503-6513.

  9. Zhang X, Luan J, Chen W, Fan J, Nan Y, Wang Y, Liang Y, Meng G, JuD*. Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3inflammasome activation and caspase-1-dependent pyroptosis. Nanoscale. 2018;10:9141-9152.

  10. Zhang X, Fan J, Wang S, Li Y, Wang Y, Li S, Luan J, Wang Z, Song P,Chen Q, Tian W, Ju D*. Targeting CD47 and autophagy elicited enhancedanti-tumor effects in non-small cell lung cancer. Cancer Immunology Research. 2017; 5:363-375. (Spotlight Research)

  11. Zhang X, Gu Y, Chen T, Yang D, Wang X, Jiang B, Shao K, Zhao W,Wang C, Wang J, Zhang Q, Liu H*. Synthesis, in vitro and in vivo anticanceractivities of novel 4-substituted 1,2-bis(4-chlorophenyl)-pyrazolidine-3,5-dione derivatives. MedChemComm. 2015, 6:1781-1786.



打印 返回